Letybo

Botulinum toxin type A, the active ingredient in Letybo, is a neuromuscular blocker presented as a sterile injectable for intramuscular use. It temporarily reduces muscle activity and is employed in therapeutic and aesthetic indications where localized muscle relaxation is required.

GNH USA supplies Letybo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Letybo, a botulinum toxin type A product, is used in several neuromuscular and cosmetic conditions where targeted muscle relaxation is needed. - Cervical dystonia: reduces abnormal neck muscle contractions and improves head posture. - Blepharospasm: relieves involuntary eyelid closure and associated discomfort. - Chronic migraine: decreases frequency of migraine days in adults with refractory migraine. - Upper‑limb spasticity: diminishes muscle tone to facilitate rehabilitation. - Hyperhidrosis: limits excessive sweating by blocking acetylcholine release in sweat glands.

Letybo may cause a range of adverse reactions following intramuscular injection.

Common Side Effects: - Injection site pain or tenderness. - Bruising or erythema at the injection site. - Headache or flu‑like symptoms. - Localized muscle weakness. - Dry mouth. - Transient vision changes.

Serious or Rare Side Effects: - Dysphagia or difficulty swallowing. - Respiratory compromise due to spread of toxin. - Generalised muscle weakness. - Anaphylactic reaction. - Systemic botulism‑like syndrome. - Persistent ptosis or eyelid droop.

Before using Letybo, clinicians should consider several safety measures. - Contraindication: Known hypersensitivity to botulinum toxin type A or any excipients. - Caution: Use in patients with neuromuscular disorders such as myasthenia gravis. - Pregnancy: Safety not established; prescribe only if potential benefit justifies risk. - Breastfeeding: Limited data; weigh benefits against potential infant exposure. - Interaction: Avoid concurrent use of other botulinum toxin products. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Botulinum toxin type A can interact with other agents that affect neuromuscular transmission.

Major Interactions (Avoid): - Aminoglycoside antibiotics (e.g., gentamicin): may potentiate neuromuscular blockade. - Non‑depolarising muscle relaxants (e.g., rocuronium): increased risk of profound weakness. - Quinine or quinidine: can enhance toxin effects.

Moderate Interactions (Monitor Closely): - Calcium channel blockers (e.g., verapamil): may alter muscle response. - Anticholinergic drugs: potential additive effect on muscle tone. - Other botulinum toxin preparations: risk of cumulative toxicity.